Our innovative preclinical solutions empower your drug development journey with cutting-edge analytics and insights from inception to preclinical stages.
We help you navigate complex trial phases efficiently with data-driven methods & strategies tailored to Phase I-III trials for accelerated drug development.
Maximize your market potential and optimize your commercial strategies with our advanced analytical methods, data science, and tailored commercialization solutions for data-driven commercial success.
Harness the power of real-world data and real-world evidence to gather insights and shape future drug development cycles for enhanced efficacy and regulatory compliance.
Craft optimal trial designs with our advanced analytical methods to enhance efficiency and increase the probability of success throughout your drug’s lifecycle.
Empower your trial delivery by transforming trial designs into actionable strategies with our data-driven approach to ensure seamless delivery and successful outcomes.
We offer tailored analytics solutions for your specialized or niche projects enabling you to optimize both efficiency and precision in drug development.
Experience the future of flexible strategic partnerships with Analytics on Demand, providing adaptive and innovative solutions that transcend traditional models to achieve unparalleled operational excellence.
Maximize efficiency and outcomes with our project-based services, delivering specialized expertise, end-to-end biometrics, and focused solutions for unique projects, ensuring timely completion and exceptional results.
Cytel's software platform enables precise trial design and simulation, utilizing adaptive and Bayesian tools to optimize protocols and accelerate drug development with confidence and efficiency.
Trial Implementation and Decision Support Software
Our unique software package streamlines trial implementation with intuitive solutions for protocol development, randomization, and patient management, optimizing operational efficiency and ensuring study success.
Discover comprehensive solutions for every stage of development — from data and regulatory strategies to Phase I-IV clinical trials, market access planning, and beyond.
Learn about our rich history, visionary leadership, and core values. Our mission and vision drive us to deliver excellence in drug development globally.
Join our innovative team at Cytel! Explore exciting career opportunities in data science and statistics, analytical methods, and regulatory strategy. Advance the future of human health with us.
Our innovative preclinical solutions empower your drug development journey with cutting-edge analytics and insights from inception to preclinical stages.
We help you navigate complex trial phases efficiently with data-driven methods & strategies tailored to Phase I-III trials for accelerated drug development.
Maximize your market potential and optimize your commercial strategies with our advanced analytical methods, data science, and tailored commercialization solutions for data-driven commercial success.
Harness the power of real-world data and real-world evidence to gather insights and shape future drug development cycles for enhanced efficacy and regulatory compliance.
Craft optimal trial designs with our advanced analytical methods to enhance efficiency and increase the probability of success throughout your drug’s lifecycle.
Empower your trial delivery by transforming trial designs into actionable strategies with our data-driven approach to ensure seamless delivery and successful outcomes.
We offer tailored analytics solutions for your specialized or niche projects enabling you to optimize both efficiency and precision in drug development.
Experience the future of flexible strategic partnerships with Analytics on Demand, providing adaptive and innovative solutions that transcend traditional models to achieve unparalleled operational excellence.
Maximize efficiency and outcomes with our project-based services, delivering specialized expertise, end-to-end biometrics, and focused solutions for unique projects, ensuring timely completion and exceptional results.
Cytel's software platform enables precise trial design and simulation, utilizing adaptive and Bayesian tools to optimize protocols and accelerate drug development with confidence and efficiency.
Our unique software package streamlines trial implementation with intuitive solutions for protocol development, randomization, and patient management, optimizing operational efficiency and ensuring study success.
Learn about our rich history, visionary leadership, and core values. Our mission and vision drive us to deliver excellence in drug development globally.
Join our innovative team at Cytel! Explore exciting career opportunities in data science and statistics, analytical methods, and regulatory strategy. Advance the future of human health with us.
Dive into our scientific peer-reviewed publications to explore cutting-edge research and insights from our experts in drug development, advanced analytics and biostatistics.
Treatment Outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence (RWE) Studies: Systematic Literature Review (SLR) (2022) pp. 35-48.
Durable remission for four pediatric patients with high-risk relapsed classical Hodgkin lymphoma treated with brentuximab vedotin plus gemcitabine but without autologous stem cell transplantation: A report from the Children’s Oncology Group (2022).
Why are not There More Bayesian Clinical Trials? Perceived Barriers and Educational Preferences Among Medical Researchers Involved in Drug Development (2022).
Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial (2022).
Developing a Prediction Model for Pathologic Complete Response Following Neoadjuvant Chemotherapy in Breast Cancer: A Comparison of Model Building Approaches (2022).
Comparison of Mortality Risk With Different Surgeon and Hospital Operative Volumes Among Individuals Undergoing Pancreatectomy by Emulating Target Trials in US Medicare Beneficiaries (2022).
Assessment of the Cow’s Milk-related Symptom Score (CoMiSS) as a diagnostic tool for cow’s milk protein allergy: a prospective, multicentre study in China (MOSAIC study) (2022).
Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial (2022).
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies (2022).
Systematic review and evidence gap assessment of the clinical, quality of life, and economic burden of alpha-thalassemia. Musallam KM, Viprakasit V, Lombard L, Gilroy K, Rane A, Vinals L, Tam C, Rizzo M, Coates TD. EJHaem. 2024
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial. P. Moreau, C. Hulin, A. Perrot, W. Hua et al., Lancet Oncology 2024
Cost-effectiveness analysis of the pediatric 20-valent pneumococcal conjugate vaccine compared with lower-valent alternatives in Argentina. Rey-Ares L, Ta A, Freigofaite D, Warren S, Mac Mullen M, Carballo C, Huang L., Vaccine. 2024
Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study. Costa Clemens SA, Jepson B, Bhorat QE, Ahmad A, Akhund T, Aley PK, Bansal H, Bibi S, Kelly EJ, Khan M, Lambe T, Lombaard JJ, Matthews S, Pipolo Milan E, Olsson U, Ramasamy MN, Moura de Oliveira Paiva MS, Seegobin S, Shoemaker K, Szylak A, Villafana T, Pollard AJ, Green JA; AZD2816 Study Group., Lancet Microbe. 2024
Seasonal human coronavirus humoral responses in AZD1222 (ChaAdOx1 nCoV-19) COVID-19 vaccinated adults reveal limited cross-immunity. Stanley AM, Aksyuk AA, Wilkins D, Green JA, Lan D, Shoemaker K, Tieu HV, Sobieszczyk ME, Falsey AR, Kelly EJ., Front Immunol. 2024
2024
Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life. Hosman T, van Heesbeen R, Bastian AR, Hu W, Comeaux C, Ligtenberg N, van Montfort B, Callendret B, Heijnen E., Hum Vaccin Immunother. 2024
Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis. Ta A, Kühne F, Laurenz M, von Eiff C, Warren S, Perdrizet., J. Infect Dis Ther. 202
A Post-Marketing Surveillance Study of Nusinersen for Spinal Muscular Atrophy in Routine Medical Practice in China: Interim Results. Jiang Y, Wang Y, Xiong H, Li W, Luo R, Chen W, Yin F, Lü J, Liang J, Chen WJ, Lu X, Wang H, Tang J, Monine M, Makepeace C, Jin X, Foster R, Chin R, Berger Z., Adv Ther. 2024
Opportunity and accessibility: an environmental scan of publicly available data repositories to address disparities in healthcare decision-making. Vinals L, Radhakrishnan A, Sarri G., Int J Equity Health. 2024
Editorial: Novel methods and technologies for the evaluation of drug outcomes and policies. Adamson B, Makady A, Sarri G, Mohamed O, Babar Z, Dawoud DM., Front Pharmacol. 2024
Impact of patient support programmes among patients with severe asthma treated with biological therapies: a systematic literature review and indirect treatment comparison. Rabe APJ, Loke WJ, Kielar D, Morris T, Shih VH, Olinger L, Musat MG, Lan Z, Harricharan S, Fulton O, Majeed A, Heaney LG., BMJ Open Respir Res. 2024
Real-world experience with filgotinib for rheumatoid arthritis in Germany : A retrospective chart review. Schultz O, Fiehn C, Kneitz C, Picker N, Kromer D, Zignani M, De Leonardis F, Orzechowski HD, Gurrath M, Krüger K. Z, Rheumatol. 2024
Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma. Dimopoulos M, Sonneveld P, Manier S, Lam A, Roccia T, Schecter JM, Cost P, Pacaud L, Poirier A, Tremblay G, Lan T, Valluri S, Kumar S., BMC Cancer. 2024
Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States. Herring WL, Gallagher ME, Shah N, Morse KC, Mladsi D, Dong OM, Chawla A, Leiding JW, Zhang L, Paramore C, Andemariam B., Pharmacoeconomics. 2024
Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis. Niegisch G, Grimm MO, Hardtstock F, Krieger J, Starry A, Osowski U, Guenther S, Deiters B, Maywald U, Wilke T, Kearney M., Future Oncol. 2024
Characteristics of Users and New Initiators of Single- and Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in Germany. Beeh KM, Rothnie KJ, Claussen J, Hardtstock F, Knapp RK, Wilke T, Czira A, Compton C, Ismaila AS., Int J Chron Obstruct Pulmon Dis. 2024
Healthcare resource utilization and associated costs in patients with metastatic urothelial carcinoma: a real-world analysis using German claims data. Niegisch G, Grimm MO, Hardtstock F, Krieger J, Starry A, Osowski U, Deiters B, Maywald U, Wilke T, Kearney M., J Med Econ. 2024
An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial. Saraf A, Gurjar R, Kaviraj S, Kulkarni A, Kumar D, Kulkarni R, Virkar R, Krishnan J, Yadav A, Baranwal E, Singh A, Raghuwanshi A, Agarwal P, Savergave L, Singh S; GEMCOVAC-OM Study Investigators., Nat Med. 2024
The Inflation Reduction Act: An Opportunity to Accelerate Confidence in Real-World Evidence in the United States. Arora P, Gupta A, Mackay E, Heeg B, Thorlund K., Value Health. 2024
Factors associated with discontinuation of treatment for pulmonary arterial hypertension in the United States. Farber HW, Germack HD, Croteau NS, Simeone JC, Tang F, Paoli CJ, Doad G, Panjabi S, De Marco T., Pulm Circ. 2024
Real-world evidence of treatment patterns and survival of metastatic gastric cancer patients in Germany. Luna J, Picker N, Wilke T, Lutz M, Hess J, Mörtl B, Xiong Y, Götze TO., BMC Cancer. 2024
Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer. Struebing A, McKibbon C, Ruan H, Mackay E, Dennis N, Velummailum R, He P, Tanaka Y, Xiong Y, Springford A, Rosenlund M., J Comp Eff Res. 2024
Effectiveness of Single-Tablet Combination Therapy in Improving Adherence and Persistence and the Relation to Clinical and Economic Outcomes. Paoli CJ, Linder J, Gurjar K, Thakur D, Wyckmans J, Grieve S., J Health Econ Outcomes Res. 2024
Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review. Raad A, Rizzo M, Appiah K, Kearns I, Hernandez L., Pharmacoeconomics. 2024
Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn’s disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies. D’Haens G, Baert F, Danese S, Kobayashi T, Loftus EV Jr, Sandborn WJ, Dornic Q, Lindner D, Kisfalvi K, Marins EG, Vermeire S., Eur J Gastroenterol Hepatol. 2024
Epidemiology of Diagnosed Age-related Macular Degeneration in Germany: An Evaluation of the Prevalence Using AOK PLUS Claims Data. Schuster AK, Leisle L, Picker N, Bubendorfer-Vorwerk H, Lewis P, Hahn P, Wasem J, Finger RP., Ophthalmol Ther. 2024
Epidemiology and Real-World Treatment of Incident Diffuse Large B-cell Lymphoma (DLBCL): A German Claims Data Analysis. Pacis S, Bolzani A, Heuck A, Gossens K, Kruse M, Fritz B, Maywald U, Wilke T, Kunz C., Oncol Ther. 2024
A matching-adjusted indirect comparison of results from REDUCE and RESPECT-two randomized trials on patent foramen ovale closure devices to prevent recurrent cryptogenic stroke. Kasner SE, Sondergaard L, Nakum M, Gomez Montero M, Hashim M, Landaas EJ., J Med Econ. 2024
Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis. Gossec L, Humphries B, Rutherford M, Taieb V, Willems D, Tillett W., Arthritis Res Ther. 2024
Clinical outcomes for previously treated patients with advanced biliary tract cancer: a meta-analysis. Amonkar MM, Abderhalden LA, Fox GE, Frederickson AM, Grira T, Gozman A, Malhotra U, Malbecq W, Akers KG., Future Oncol. 2024
A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma. Mol I, Hu Y, LeBlanc TW, Cappelleri JC, Chu H, Nador G, Aydin D, Schepart A, Hlavacek P., Leuk Lymphoma. 2024
Value-based pricing: a potential solution to difficult pricing discussions and payers’ negotiations. Tremblay G, Poirier A, Monfort L., J Med Econ. 2024
Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension. Grünig E, Jansa P, Fan F, Hauser JA, Pannaux M, Morganti A, Rofael H, Chin KM., J Am Coll Cardiol. 2024
Navigating the unknown: how to best ‘reflect’ standard of care in indications without a dedicated treatment pathway in health technology assessment submissions. Sarri G, Rizzo M, Upadhyaya S, Paly VF, Hernandez L., J Comp Eff Res. 2024
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials. Lebwohl M, Warren RB, Sofen H, Imafuku S, Paul C, Szepietowski JC, Spelman L, Passeron T, Vritzali E, Napoli A, Kisa RM, Buck A, Banerjee S, Thaçi D, Blauvelt A., Br J Dermatol. 2024
Quantitative bias analysis for external control arms using real-world data in clinical in trials: a primer for clinical researchers. Thorlund K, Duffield S, Popat S, Ramagopalan S, Gupta A, Hsu G, Arora P, Subbiah V., J Comp Eff Res. 2024
Justifying the source of external comparators in single-arm oncology health technology submissions: a review of NICE and PBAC assessments. Appiah K, Rizzo M, Sarri G, Hernandez L., J Comp Eff Res. 2024
Real-world treatment patterns in patients initiating third-line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain. Lehne M, Kortüm KM, Ramasamy K, Zamagni E, d’Estrubé T, Zhuleku E, Hanna M, Shukla S, Ghiani M, Maywald U, Wilke T, Kellermann L, Perera S., Eur J Haematol. 2024
Claims-based algorithm to estimate the Expanded Disability Status Scale for multiple sclerosis in a German health insurance fund: a validation study using patient medical records. Muros-Le Rouzic E, Ghiani M, Zhuleku E, Dillenseger A, Maywald U, Wilke T, Ziemssen T, Craveiro L., Front Neurol. 2023
Improved estimation of overall survival and progression-free survival for state transition modeling. Wigfield PC, Heeg B, Ouwens M., J Comp Eff Res. 2024
A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma. Mol I, Hu Y, LeBlanc TW, Cappelleri JC, Chu H, Nador G, Aydin D, Schepart A, Hlavacek P., Curr Med Res Opin. 2024
Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study. Jackson DJ, Heaney LG, Humbert M, Kent BD, Shavit A, Hiljemark L, Olinger L, Cohen D, Menzies-Gow A, Korn S; SHAMAL Investigators., Lancet. 2024
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis. Rudwaleit M, Mørup MF, Humphries B, Zannat NE, Willems D, Taieb V, Boonen A., RMD Open. 2023
Liver disease epidemiology and burden in patients with alterations in plasma protein metabolism: German retrospective insurance claims analysis. Picker N, Hagiwara M, Baumann S, Marins EG, Wilke T, Ren K, Maywald U, Karki C, Strnad P., World J Hepatol. 2023
Association between treatment and improvements in overall survival of patients with advanced/metastatic non-small cell lung cancer since 2011: A study in the United States, Canada, and Germany using retrospective real-world databases. Griesinger F, Ramagopalan S, Cheung WY, Wilke T, Mueller S, Gupta A, O’Sullivan DE, Arora P, Brenner DR, Froelich C, Inskip J, Maywald U, Subbiah V., Cancer. 2024
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Hopewell S, Ursino M, Rantell KR, Calvert M, Lee S, Kightley A, Ashby D, Chan AW, Garrett-Mayer E, Isaacs JD, Golub R, Kholmanskikh O, Richards D, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, Dimairo M, Weir CJ., BMJ. 2023
Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance. Yap C, Rekowski J, Ursino M, Solovyeva O, Patel D, Dimairo M, Weir CJ, Chan AW, Jaki T, Mander A, Evans TRJ, Peck R, Hayward KS, Calvert M, Rantell KR, Lee S, Kightley A, Hopewell S, Ashby D, Garrett-Mayer E, Isaacs J, Golub R, Kholmanskikh O, Richards DP, Boix O, Matcham J, Seymour L, Ivy SP, Marshall LV, Hommais A, Liu R, Tanaka Y, Berlin J, Espinasse A, de Bono J., BMJ. 2023
Author Correction: Early-childhood linear growth faltering in low- and middle-income countries. Benjamin-Chung J, Mertens A, Colford JM Jr, Hubbard AE, van der Laan MJ, Coyle J, Sofrygin O, Cai W, Nguyen A, Pokpongkiat NN, Djajadi S, Seth A, Jilek W, Jung E, Chung EO, Rosete S, Hejazi N, Malenica I, Li H, Hafen R, Subramoney V, Häggström J, Norman T, Brown KH, Christian P, Arnold BF; Ki Child Growth Consortium., Nature. 2023
Global Burden of Asthma, and Its Impact on Specific Subgroups: Nasal Polyps, Allergic Rhinitis, Severe Asthma, Eosinophilic Asthma. Rabe APJ, Loke WJ, Gurjar K, Brackley A, Lucero-Prisno Iii DE., J Asthma Allergy. 2023
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland. Ramasamy MN, Kelly EJ, Seegobin S, Dargan PI, Payne R, Libri V, Adam M, Aley PK, Martinez-Alier N, Church A, Jepson B, Khan M, Matthews S, Townsend GT, Vekemans J, Bibi S, Swanson PA 2nd, Lambe T, Pangalos MN, Villafana T, Pollard AJ, Green JA; AZD2816 Study Group., Lancet Microbe. 2023
Pretest PSA and Restaging PSMA PET/CT Predict Survival in Biochemically Recurrent Prostate Cancer. von Eyben R, Hoffmann MA, Soydal C, Virgolini I, Tuncel M, Gauthé M, Kapp DS, von Eyben FE., Biomedicines. 2023
Earlier Use of Long-Acting Injectable Paliperidone Palmitate Versus Oral Antipsychotics in Patients With Schizophrenia: An Integrated Patient-Level Post Hoc Analysis. Lopena OJ, Alphs LD, Sajatovic M, Turkoz I, Sun L, Johnston KL, Sliwa JK, Najarian DM, Starr HL., J Clin Psychiatry. 2023
The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and meta-analysis. van Hylckama Vlieg MAM, Nasserinejad K, Visser C, Bramer WM, Ashrani AA, Bosson JL, Crusan DJ, D’Alessio A, Fluharty ME, Ģībietis V, Hansson PO, Hara N, Jara-Palomares L, Kraaijpoel N, Mahé I, Marshall A, Ogino Y, Otero R, Versmissen J, Klok FA, Kruip MJHA, van der Rijt CCD, Geijteman ECT., EClinicalMedicine. 2023
Cost-effectiveness analysis of bimekizumab for the treatment of active psoriatic arthritis in Sweden. Sigurdardottir V, Engstrom A, Berling P, Olofsson T, Oldsberg L, Sadler S, Parra-Padilla D, Melis L, Willems D., J Med Econ. 2023
Causes and consequences of child growth faltering in low-resource settings. Mertens A, Benjamin-Chung J, Colford JM Jr, Coyle J, van der Laan MJ, Hubbard AE, Rosete S, Malenica I, Hejazi N, Sofrygin O, Cai W, Li H, Nguyen A, Pokpongkiat NN, Djajadi S, Seth A, Jung E, Chung EO, Jilek W, Subramoney V, Hafen R, Häggström J, Norman T, Brown KH, Christian P, Arnold BF; Ki Child Growth Consortium., Nature. 2023
Child wasting and concurrent stunting in low- and middle-income countries. Mertens A, Benjamin-Chung J, Colford JM Jr, Hubbard AE, van der Laan MJ, Coyle J, Sofrygin O, Cai W, Jilek W, Rosete S, Nguyen A, Pokpongkiat NN, Djajadi S, Seth A, Jung E, Chung EO, Malenica I, Hejazi N, Li H, Hafen R, Subramoney V, Häggström J, Norman T, Christian P, Brown KH, Arnold BF; Ki Child Growth Consortium., Nature. 2023
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
EN 
FR 
